. 2011 Mar 15;203(6):780–790. doi: 10.1093/infdis/jiq118

Table 3.

The Increased Risk for Mortality Conferred by Higher sCD14 Levels Does Not Differ between Treatment Arms

	Drug conservation arm		Viral suppression arm
Biomarker	OR (95% CI)^a	P	OR (95% CI)	P	P for interaction
sCD14 level, ×10⁶ pg/mL	3.5 (1.5–8.3)	.004	2.0 (0.8–5.4)	.15	.43
LPS, pg/mL	1.0 (0.6–1.7)	.96	0.7 (0.3–1.7)	.40	.63
I-FABP, pg/mL	0.9 (0.4–2.1)	.84	2.3 (0.6–8.8)	.19	.58
16S rDNA, copies/μL	0.9 (0.4–2.2)	.90	0.5 (0.2–1.4)	.21	.26
EndoCAb, MMU/mL	1.1 (0.8–1.6)	.49	0.9 (0.6–1.4)	.66	.57

NOTE. No biomarker other than sCD14 was associated with mortality in either treatment arm. CI, confidence interval; EndoCAb, endotoxin core antibody; I-FABP, intestinal fatty acid binding protein; LPS, lipopolysaccharide; OR, odds ratio; rDNA, ribosomal DNA; sCD14, soluble CD14.

OR based on univariate analysis derived from conditional logistic model, associated with a one interquartile range higher level of biomarker after log₁₀ transformation.